期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 14, 期 3, 页码 255-264出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2016.0031
关键词
-
类别
资金
- AstraZeneca
- Bayer Healthcare Pharmaceuticals Inc.
- Bristol-Myers Squibb
- Clovis Oncology
- Genentech
- Novartis Oncology
- Otsuka America Pharmaceutical, Inc.
- Seattle Genetics, Inc.
- Takeda Oncology
- Actelion Pharmaceuticals US, Inc.
- Astellas and Medivation, Inc.
These NCCN Guidelines Insights focus on recent updates in the 2016 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC; Versions 1-4). These NCCN Guidelines Insights will discuss new immunotherapeutic agents, such as nivolumab and pembrolizumab, for patients with metastatic NSCLC. For the 2016 update, the NCCN panel recommends immune checkpoint inhibitors as preferred agents (in the absence of contraindications) for second-line and beyond (subsequent) therapy in patients with metastatic NSCLC (both squamous and nonsquamous histologies). Nivolumab and pembrolizumab are preferred based on improved overall survival rates, higher response rates, longer duration of response, and fewer adverse events when compared with docetaxel therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据